| Literature DB >> 35225813 |
Maryanne Kim1,2, Youran Noh1,2, Akihiko Yamada1, Song Hee Hong1,2.
Abstract
BACKGROUND: Topic modeling of patient medication reviews of erectile dysfunction (ED) drugs can help identify patient preferences regarding ED treatment options. The identification of a set of topics important to the patient from social network service drug reviews would inform the design of patient-centered medication counseling.Entities:
Keywords: PDE5 inhibitor; erectile dysfunction; patient preference; patient-centered communication; phosphodiesterase type 5 inhibitor; topic modeling
Year: 2022 PMID: 35225813 PMCID: PMC8922152 DOI: 10.2196/32689
Source DB: PubMed Journal: JMIR Med Inform
Characteristics of patient medication reviews.
| Demographic | Sildenafil (N=463), n (%) | Tadalafil (N=919), n (%) | |||
|
|
|
| |||
|
| Male | 445 (96.1) | 869 (94.6) | ||
|
| Female | 7 (1.5) | 16 (1.7) | ||
|
| Not available | 11 (2.4) | 34 (3.7) | ||
|
|
|
| |||
|
| 19-44 | 124 (26.8) | 225 (24.5) | ||
|
| 45-64 | 257 (55.5) | 559 (60.8) | ||
|
| ≥65 | 82 (17.7) | 135 (14.7) | ||
|
|
|
| |||
|
| <1 month | 163 (35.2) | 448 (48.7) | ||
|
| 1 month to <1 year | 141 (30.5) | 240 (26.1) | ||
|
| ≥1 year | 150 (32.4) | 187 (20.3) | ||
|
| Not available | 9 (1.9) | 44 (4.8) | ||
|
|
|
| |||
|
| Inability to have an erection | 166 (81.8) | 253 (73.8) | ||
|
| Increased pressure of pulmonary circulation | 5 (2.4) | 5 (1.5) | ||
|
| Pulmonary arterial hypertension | 2 (1.0) | 1 (0.3) | ||
|
| Enlarged prostate | —b | 22 (6.4) | ||
|
| Enlarged prostate with urination problems | —b | 10 (2.9) | ||
|
| Other | 30 (14.8) | 52 (15.2) | ||
|
|
|
| |||
|
| Caregiver | 3 (1.5) | 13 (3.8) | ||
|
| Patient | 189 (93.1) | 311 (90.7) | ||
|
| Not available | 11 (5.4) | 19 (5.5) | ||
|
|
|
| |||
|
| 2001-2004 | 21 (4.5) | —b | ||
|
| 2005-2009 | 201 (43.4) | 343 (37.3) | ||
|
| 2010-2014 | 179 (38.7) | 424 (46.1) | ||
|
| 2015-2019 | 62 (13.4) | 152 (16.5) | ||
aOnly the reviews posted on WebMD have this information.
bNot available.
Figure 1Topic distribution of erectile dysfunction therapy by age and time on medication. mth: month; yr: year.
Drug ratings of sildenafil by age and time on medication.
| Variable | Overall rating, mean (SD) | Rating by age (years), mean (SD) | Rating by time on medication, mean (SD) | ||||||
|
|
| 19-44 | 45-64 | ≥65 | <1 month | 1 month to <1 year | ≥1 year | ||
| Sexual performance | 3.94 (1.42) | 4.32 (1.25) | 4.02 (1.38) | 3.44 (1.56) | .09 | 3.27 (1.73) | 4.26 (1.33) | 4.08 (1.16) | .02 |
| Erection sustainability | 3.85 (1.42) | 4.37 (1.03) | 3.82 (1.40) | 2.86 (1.75) | .004 | 3.64 (1.42) | 3.89 (1.49) | 4.10 (1.37) | .50 |
| Blue magic | 3.58 (1.50) | 3.70 (1.40) | 3.60 (1.53) | 3.25 (1.60) | .70 | 3.22 (1.53) | 3.53 (1.55) | 4.15 (1.29) | .04 |
| Medication safety | 3.30 (1.49) | 2.56 (1.58) | 3.70 (1.39) | 3.46 (0.97) | .001 | 2.41 (1.42) | 3.77 (1.45) | 3.91 (1.09) | <.001 |
| Alternative choices | 3.83 (1.51) | 4.33 (1.40) | 4.00 (1.38) | 2.94 (1.65) | .02 | 3.56 (1.75) | 3.70 (1.64) | 4.22 (1.09) | .28 |
| Total | 3.68 (1.48) | 3.73 (1.53) | 3.82 (1.42) | 3.20 (1.52) | .004 | 3.16 (1.59) | 3.88 (1.48) | 4.08 (1.18) | <.001 |
Drug ratings of tadalafil by age and time on medication.
| Variable | Overall rating, mean (SD) | Rating by age (years), mean (SD) | Rating by time on medication, mean (SD) | ||||||
|
|
| 19-44 | 45-64 | ≥65 | <1 month | 1 month to <1 year | ≥1 year | ||
| Sexual performance | 4.14 (1.29) | 4.17 (1.15) | 4.37 (1.12) | 3.29 (1.70) | <.001 | 4.05 (1.27) | 4.03 (1.47) | 4.33 (1.13) | .48 |
| Amber romance | 3.81 (1.45) | 3.68 (1.38) | 3.89 (1.45) | 3.79 (1.69) | .73 | 3.32 (1.53) | 4.44 (1.12) | 4.35 (0.99) | <.001 |
| Mild medication safety | 3.52 (1.52) | 3.23 (1.61) | 3.64 (1.49) | 3.57 (1.43) | .30 | 3.07 (1.53) | 4.06 (1.25) | 4.00 (1.27) | <.001 |
| Serious medication safety | 2.44 (1.46) | 2.34 (1.28) | 2.47 (1.51) | 2.50 (1.64) | .84 | 2.24 (1.39) | 2.92 (1.42) | 3.32 (1.73) | <.001 |
| Alternative choices | 3.53 (1.59) | 3.74 (1.54) | 3.45 (1.62) | 3.56 (1.57) | .65 | 3.03 (1.82) | 3.77 (1.41) | 3.89 (1.37) | .005 |
| Total | 3.39 (1.59) | 3.31 (1.54) | 3.42 (1.61) | 3.39 (1.62) | .65 | 2.91 (1.61) | 3.87 (1.42) | 4.01 (1.32) | <.001 |
Figure 2Comparison of treatment satisfaction by primary topics between sildenafil and tadalafil. mth: month; yr: year.